Get started
Author

Fabien Claves

Observed names: Claves, Fabien, F. Claves
ORCID: 0009-0002-6468-0001
Observed ORCID: 0009-0002-6468-0001
OpenAlex ID: A5063514274
Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma
2021 · Fabien Claves, Romane Siest, et al. · Journal of Clinical Immunology · 11
Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry
2025 · Federico Erbella, Emmanuel Bachy, et al. · Blood Advances · 10
PDF
Large B-cell lymphoma: The LYSA pragmatic guidelines
2025 · Pierre Sesques, Guillaume Manson, et al. · European Journal of Cancer · 7
PDF
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma
2025 · Vincent Camus, Thierry Molina, et al. · Blood Advances · 7
PDF
Atypical meningeal localization of classical hairy cell leukemia with an impressive response to rituximab and cladribine association. A case report and literature review
2024 · Fabien Claves, Sylvain Carras, et al. · eJHaem · 5
PDF
Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
2024 · Vincent Camus, Thierry Jo Molina, et al. · Blood · 2
PDF
Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study
2026 · Carl Johan Rudebeck, Luc Matthieu Fornecker, et al. · Haematologica
PDF
Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group
2026 · Pierre Sesques, Guillaume Manson, et al. · HemaSphere
Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group
2025 · Loïc Renaud, Florian Chevillon, et al. · Blood
PDF
Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry
2025 · Pierre Sesques, Guillaume Manson, et al. · Blood
371 | Synthetic Control Arm From Clinical Trial and Real‐world Cohorts From Lysa Group for Untreated Older Classical Hodgkin Lymphoma for Innovative Clinical Trial Designs
2025 · H. Ghesquieres, F. Claves, et al. · Hematological Oncology
PDF
381 | Cd19 Car‐t Cell Therapy in Relapsed/refractory Solid Organ Transplant‐related Lymphoproliferation: a Lysa Analysis of the French Cohort Descar‐t
2025 · E. Corvilain, R. Di blasi, et al. · Hematological Oncology
PDF
Postoperative stage 0 Hodgkin lymphoma. Is surgery alone a curative option?
2025 · Audrey Couturier, Alexandra Judet, et al. · HemaSphere
PDF
Works count: 14
Citation count: 37
H-index: 5
I10-index: 1
Year
Topic
Type